These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 16540318)

  • 1. Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists.
    Ho KK; Auld DS; Bohnstedt AC; Conti P; Dokter W; Erickson S; Feng D; Inglese J; Kingsbury C; Kultgen SG; Liu RQ; Masterson CM; Ohlmeyer M; Rong Y; Rooseboom M; Roughton A; Samama P; Smit MJ; Son E; van der Louw J; Vogel G; Webb M; Wijkmans J; You M
    Bioorg Med Chem Lett; 2006 May; 16(10):2724-8. PubMed ID: 16540318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hit-to-Lead studies: the discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists.
    Baxter A; Cooper A; Kinchin E; Moakes K; Unitt J; Wallace A
    Bioorg Med Chem Lett; 2006 Feb; 16(4):960-3. PubMed ID: 16297626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and evaluation of novel 3-amino-4-hydrazine-cyclobut-3-ene-1,2-diones as potent and selective CXCR2 chemokine receptor antagonists.
    Liu S; Liu Y; Wang H; Ding Y; Wu H; Dong J; Wong A; Chen SH; Li G; Chan M; Sawyer N; Gervais FG; Henault M; Kargman S; Bedard LL; Han Y; Friesen R; Lobell RB; Stout DM
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5741-5. PubMed ID: 19713110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor.
    Widdowson KL; Elliott JD; Veber DF; Nie H; Rutledge MC; McCleland BW; Xiang JN; Jurewicz AJ; Hertzberg RP; Foley JJ; Griswold DE; Martin L; Lee JM; White JR; Sarau HM
    J Med Chem; 2004 Mar; 47(6):1319-21. PubMed ID: 14998320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of potent and orally bioavailable N,N'-diarylurea antagonists for the CXCR2 chemokine receptor.
    Jin Q; Nie H; McCleland BW; Widdowson KL; Palovich MR; Elliott JD; Goodman RM; Burman M; Sarau HM; Ward KW; Nord M; Orr BM; Gorycki PD; Busch-Petersen J
    Bioorg Med Chem Lett; 2004 Sep; 14(17):4375-8. PubMed ID: 15357956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The discovery of potent, orally bioavailable pyrimidine-5-carbonitrile-6-alkyl CXCR2 receptor antagonists.
    Porter DW; Bradley M; Brown Z; Charlton SJ; Cox B; Hunt P; Janus D; Lewis S; Oakley P; O'Connor D; Reilly J; Smith N; Press NJ
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3285-90. PubMed ID: 24974342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and structure-activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists.
    Merritt JR; Rokosz LL; Nelson KH; Kaiser B; Wang W; Stauffer TM; Ozgur LE; Schilling A; Li G; Baldwin JJ; Taveras AG; Dwyer MP; Chao J
    Bioorg Med Chem Lett; 2006 Aug; 16(15):4107-10. PubMed ID: 16697193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.
    Dwyer MP; Yu Y; Chao J; Aki C; Chao J; Biju P; Girijavallabhan V; Rindgen D; Bond R; Mayer-Ezel R; Jakway J; Hipkin RW; Fossetta J; Gonsiorek W; Bian H; Fan X; Terminelli C; Fine J; Lundell D; Merritt JR; Rokosz LL; Kaiser B; Li G; Wang W; Stauffer T; Ozgur L; Baldwin J; Taveras AG
    J Med Chem; 2006 Dec; 49(26):7603-6. PubMed ID: 17181143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists.
    Chao J; Taveras AG; Chao J; Aki C; Dwyer M; Yu Y; Purakkattle B; Rindgen D; Jakway J; Hipkin W; Fosetta J; Fan X; Lundell D; Fine J; Minnicozzi M; Phillips J; Merritt JR
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3778-83. PubMed ID: 17459706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoroalkyl alpha side chain containing 3,4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists.
    Biju P; Taveras AG; Dwyer MP; Yu Y; Chao J; Hipkin RW; Fan X; Rindgen D; Fine J; Lundell D
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1431-3. PubMed ID: 19196511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists.
    Austin RP; Bennion C; Bonnert RV; Cheema L; Cook AR; Cox RJ; Ebden MR; Gaw A; Grime K; Meghani P; Nicholls D; Phillips C; Smith N; Steele J; Stonehouse JP
    Bioorg Med Chem Lett; 2015 Apr; 25(7):1616-20. PubMed ID: 25708618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region.
    Aki C; Chao J; Ferreira JA; Dwyer MP; Yu Y; Chao J; Merritt RJ; Lai G; Wu M; Hipkin RW; Fan X; Gonsiorek W; Fosseta J; Rindgen D; Fine J; Lundell D; Taveras AG; Biju P
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4446-9. PubMed ID: 19525110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a series of bicyclic CXCR2 antagonists.
    Walters I; Austin C; Austin R; Bonnert R; Cage P; Christie M; Ebden M; Gardiner S; Grahames C; Hill S; Hunt F; Jewell R; Lewis S; Martin I; David Nicholls ; David Robinson
    Bioorg Med Chem Lett; 2008 Jan; 18(2):798-803. PubMed ID: 18240390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and structure-activity relationships of new disubstituted phenyl-containing 3,4-diamino-3-cyclobutene-1,2-diones as CXCR2 receptor antagonists.
    Lai G; Merritt JR; He Z; Feng D; Chao J; Czarniecki MF; Rokosz LL; Stauffer TM; Rindgen D; Taveras AG
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1864-8. PubMed ID: 18304809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N,N'-Diarylcyanoguanidines as antagonists of the CXCR2 and CXCR1 chemokine receptors.
    Nie H; Widdowson KL; Palovich MR; Fu W; Elliott JD; Bryan DL; Burman M; Schmidt DB; Foley JJ; Sarau HM; Busch-Petersen J
    Bioorg Med Chem Lett; 2006 Nov; 16(21):5513-6. PubMed ID: 16934456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonpeptidergic allosteric antagonists differentially bind to the CXCR2 chemokine receptor.
    de Kruijf P; van Heteren J; Lim HD; Conti PG; van der Lee MM; Bosch L; Ho KK; Auld D; Ohlmeyer M; Smit MJ; Wijkmans JC; Zaman GJ; Smit MJ; Leurs R
    J Pharmacol Exp Ther; 2009 May; 329(2):783-90. PubMed ID: 19190236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SAR studies on thiazolo[4,5-d]pyrimidine based CXCR2 antagonists involving a novel tandem displacement reaction.
    Hunt F; Austin C; Austin R; Bonnert R; Cage P; Christie J; Christie M; Dixon C; Hill S; Jewell R; Martin I; Robinson D; Willis P
    Bioorg Med Chem Lett; 2007 May; 17(10):2731-4. PubMed ID: 17382543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.
    Gonsiorek W; Fan X; Hesk D; Fossetta J; Qiu H; Jakway J; Billah M; Dwyer M; Chao J; Deno G; Taveras A; Lundell DJ; Hipkin RW
    J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A common intracellular allosteric binding site for antagonists of the CXCR2 receptor.
    Salchow K; Bond ME; Evans SC; Press NJ; Charlton SJ; Hunt PA; Bradley ME
    Br J Pharmacol; 2010 Apr; 159(7):1429-39. PubMed ID: 20233217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carboxylic acid bioisosteres acylsulfonamides, acylsulfamides, and sulfonylureas as novel antagonists of the CXCR2 receptor.
    Winters MP; Crysler C; Subasinghe N; Ryan D; Leong L; Zhao S; Donatelli R; Yurkow E; Mazzulla M; Boczon L; Manthey CL; Molloy C; Raymond H; Murray L; McAlonan L; Tomczuk B
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1926-30. PubMed ID: 18308567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.